Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Work In Process came in at $59.0 million in Q2 2026, up 34.87% YoY from $43.8 million in Q2 2025, and down 9.79% on a QoQ basis from $65.5 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Work In Process data on file, last reported at $59.0 million in Q2 2026.
- Quarterly Work In Process rose 34.87% year-over-year to $59.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $59.0 million (up 34.87% YoY) and the FY2025 annual result came in at $65.1 million, changed 0.22% from the prior year.
- Work In Process retreated to $59.0 million in Q2 2026, from $65.5 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $116.7 million in Q2 2023 to a low of $35.5 million in Q3 2025.
- A 5-year average of $77.9 million and a median of $73.0 million in 2024 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2022 — Work In Process surged 295.84% — and 2025, when it plunged 49.18%.
- Tracing ALNY's Work In Process over 5 years: stood at $113.8 million in 2022, then slumped by 32.36% to $77.0 million in 2023, then dropped by 15.57% to $65.0 million in 2024, then grew by 0.22% to $65.1 million in 2025, then fell by 9.33% to $59.0 million in 2026.
- The last three Work In Process figures came in at $59.0 million (Q2 2026), $65.5 million (Q1 2026), and $65.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.05 Mn |
| Mar 31, 2026 | 65.46 Mn |
| Dec 31, 2025 | 65.12 Mn |
| Sep 30, 2025 | 35.50 Mn |
| Jun 30, 2025 | 43.78 Mn |
| Mar 31, 2025 | 53.99 Mn |
| Dec 31, 2024 | 64.98 Mn |
| Sep 30, 2024 | 69.87 Mn |
| Jun 30, 2024 | 66.54 Mn |
| Mar 31, 2024 | 76.07 Mn |
| Dec 31, 2023 | 76.96 Mn |
| Sep 30, 2023 | 88.69 Mn |
| Jun 30, 2023 | 116.66 Mn |
| Mar 31, 2023 | 110.98 Mn |
| Dec 31, 2022 | 113.78 Mn |
| Sep 30, 2022 | 102.45 Mn |
| Jun 30, 2022 | 100.19 Mn |
| Mar 31, 2022 | 91.26 Mn |
| Dec 31, 2021 | 100.94 Mn |
| Sep 30, 2021 | 33.12 Mn |